医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Invests in Genial Light, a Medical Device Development Startup

2021年03月30日 PM01:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested in Genial Light Co., Ltd., a startup that develops testing equipment and other devices for medical institutions, with the aim of promoting product development in the healthcare field.

In recent years, Toyoda Gosei has focused increasingly on innovations that exploit its core technologies in order to achieve sustainable growth during a time of great upheaval in the automotive industry. The company is pioneering new businesses and developing products in the healthcare and other fields for which there is rising social demand. Examples include the development of deep UV LEDs for bacterial and viral disinfection and e-Rubber, a new material that is promising for use as a flexible sensor.

Since its foundation in 2006, Genial Light has worked together with medical device manufacturers and applied its optical technologies to develop small inspection devices for international markets. This includes devices that provide highly accurate measurements of biological information, such as pulse and blood components, and devices that measure blood in patients’ urine and hemoglobin concentration while they are receiving dialysis.

Toyoda Gosei will integrate Genial Light’s expertise in the medical and healthcare business in accelerating practical application of products that contribute to a healthier and safer society.

Outline of Genial Light

Company name

Genial Light Co., Ltd.

Location

Taijuseimei Hamamatsu Building 8F, 145-1 Tokiwacho, Naka-ku, Hamamatsu, Shizuoka, Japan

CEO

Ryo Shimokita

Founded

November, 2006

Capital

223 million yen (as of February 28, 2021)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005188/en/

CONTACT

Toyoda Gosei Co., Ltd.

Contact: Takatomo Abe

inquiry@mail.toyoda-gosei.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
  • InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China
  • Disclosure of data on Agaricus blazei mushroom, KA21′s immunity-enhancing mechanism, immunological enhancement effect confirmed by human clinical trials, and candida and other types of fungal infection, Toei Shinyaku
  • Disclosure of data on effects of Agaricus blazei mushroom, KA21 strain for improvement of hair loss & gray hair in human clinical trials and promotion of hair growth in mice, Toei Shinyaku
  • Survey of degree of satisfaction with Agaricus blazei mushroom KA21 for promoting the health of senior dogs and cats among veterinarians and pet owners, Toei Shinyaku